MSF has made an investment in Pedicta Biosciences to support the development of advanced diagnostics to improve clinical decision-making ultimately leading to improved clinical outcomes for multiple myeloma patients. As new medicines are developed, there is an increased need for greater diagnostic information that goes beyond what traditional FISH tests provide. The Predicta Biosciences approach not only offers improved diagnostics to meet the needs for guiding clinical decisions with current and novel therapies but also can provide information to help the development of emerging medicines. Importantly, Predicta Biosciences can generate the necessary diagnostic information using complementary platforms that only require a peripheral blood sample. Therefore, this reduces the requirement and frequency of bone marrow samples.